<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="476">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <actrnumber>ACTRN12605000359639</actrnumber>
  <trial_identification>
    <studytitle>Randomised Phase II trial of de Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan in patients with previously treated metastatic colorectal cancer (DaVINCI)</studytitle>
    <scientifictitle>Randomised Phase II trial of de Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan in patients with previously treated metastatic colorectal cancer (DaVINCI)</scientifictitle>
    <utrn />
    <trialacronym>DaVINCI</trialacronym>
    <secondaryid>Australasian Gastro-Intestinal Trials Group: AG0103CR</secondaryid>
    <secondaryid>National Clinical Trials Registry: 578</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic colorectal cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Irinotecan versus irinotecan + 5-FU/leucovorin.
Duration: Until patients progress</interventions>
    <comparator>For the purposes of this study, the "Standard" therapy will be considered as single agent Irinotecan which will be compared to the combination of irinotecan/5-FU/LV</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rates of Grade 3/4 diarrhoea</outcome>
      <timepoint>Every 2 weeks (combination arm) and Every 3 weeks (single agent arm) using the CTC AE Version 3.0 scale.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of other Grade 3/4 toxicities</outcome>
      <timepoint>Every 2 weeks (combination arm) and Every 3 weeks (single agent arm) using the CTC AE Version 3.0 scale.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival measured by patient status updates during follow-up clinic visits.</outcome>
      <timepoint>At Baseline and 6 weekly for a minimum of 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life measured by the QLQ-C30 questionnaire.</outcome>
      <timepoint>Baseline and then 6 weekly</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression Free Survival assessed by CT scans using RECIST Version 1.0.</outcome>
      <timepoint>Baseline and then 6 weekly</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival measured by patient status updates during follow-up clinic visits.</outcome>
      <timepoint>Baseline and then 6 weekly</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1)  Metastatic or locally advanced colon or rectal cancer not curable by surgery or other methods.
(2)   At least one lesion evaluable for response by RECIST criteria.
(3)  Age = 18 years.
(4)  Life expectancy of at least 12 weeks.
(5)  ECOG performance status 0-2.
(6)  Confirmed progression after one prior chemotherapy regimen for advanced disease or relapse within 6 months of receiving prior adjuvant chemotherapy.  
(7)  Normal haematological tests: haemoglobin &gt;10 g/dL, WBC &gt;4.0 x 109/L, neutrophils &gt; 1.5 x 109/L, platelets &gt;100 x 109/L
(8)  Normal renal function tests, documented as serum creatinine ? 2.0 x IULN
(9)  Adequate hepatic function.  Bilirubin must be ? 1.5 x IULN  for all patients 
(10)  Patients must be geographically accessible and physically capable of completing study investigations as required
(11)  Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>(1)  Serious infection or other intercurrent illness which will prevent adequate assessment of response and toxicity.
(2)  Pregnancy or breast feeding.
(3)  Previous chemotherapy within 4 weeks of start of trial treatment.
(4)  Extensive radiotherapy within 4 weeks of start of trial therapy. 
(5)  Cerebral metastases. If the possibility of cerebral metastases is clinically indicated appropriate investigation should be undertaken before the patient is considered for participation in the study.
(6)  Evidence of Gilberts syndrome.
(7)  Prior treatment with irinotecan.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Open randomisation, not blinded</concealment>
    <sequence>Computer generation software, stratification using blocking.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>9/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD,SA,WA,TAS</recruitmentstate>
    <postcode>2050</postcode>
    <postcode>2050</postcode>
    <postcode>2050</postcode>
    <postcode>2050, 2137, 2031, 3350, 3084, 3065, 7000, 6000, 6009, 6008, 6230,</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch, South Island, New Zealand</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>AGITG</primarysponsorname>
    <primarysponsoraddress>GI CANCER Institute
Medical Foundation Building
University of Sydney
Level 6 92-94 Parramatta Road
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Educational Grant</fundingname>
      <fundingaddress>West Ryde, NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>NHMRC Clinical Trials Centre, University of Sydney</othercollaboratorname>
      <othercollaboratoraddress>Locked Bag 77
Camperdown NSW 1450</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The DaVINCI trial closed to recruitment on 31st January 2008. 89 patients were recruited from Australia and New Zealand</summary>
    <trialwebsite>http://www.gicancer.org.au/
http://www.ctc.usyd.edu.au/</trialwebsite>
    <publication>Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. Stephen J. Clarke, Sonia Yip, Chris Brown, Guy A. van Hazel, David T. Ransom, David Goldstein, G. Mark Jeffrey, Niall C. Tebbutt, Martin Buck, Raymond M. Lowenthal, Amy Boland, Val Gebski, John Zalcberg, R. John Simes, on behalf of the Australasian Gastro-Intestinal Trials Group. European Journal of Cancer
Volume 47, Issue 12 , Pages 1826-1836, August 2011.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Concord Repatriation General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress> Melbourne</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>DAVINCI Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>agitg_operations@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>DAVINCI Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>agitg_operations@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>DAVINCI Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre Locked Bag 77 Camperdown NSW 1450</address>
      <phone>+61 2 9562 5000</phone>
      <fax>+61 2 9562 5094</fax>
      <email>agitg_operations@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>